<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992182</url>
  </required_header>
  <id_info>
    <org_study_id>2021-71</org_study_id>
    <nct_id>NCT04992182</nct_id>
  </id_info>
  <brief_title>Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster</brief_title>
  <acronym>REFUERZO</acronym>
  <official_title>Reactogenicidad, Seguridad e Inmunogenicidad de Dosis de Refuerzo de Vacunas Contra SARS-CoV-2 en Chile (Estudio REFUERZO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad del Desarrollo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad del Desarrollo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary data suggest that inactivated vaccine-induced neutralizing antibodies against&#xD;
      SARS-CoV-2 decrease at six months after vaccination. Observational, unpublished data also&#xD;
      indicate that vaccine effectiveness against Covid-19 wanes over time. Thus, the investigators&#xD;
      aimed to determine the reactogenicity, safety, and immunogenicity of a homologous or&#xD;
      heterologous booster of SARS-CoV-2 vaccines among people already immunized with an&#xD;
      inactivated SARS-CoV-2 vaccine. The study focuses on the elderly population and healthcare&#xD;
      workers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early humoral response</measure>
    <time_frame>Baseline (90-120 days after second dose of CoronaVac) and 15 days post booster dose</time_frame>
    <description>Change in SARS-CoV-2 neutralizing antibody levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline, 15, 30, 60, and 90 days post booster dose</time_frame>
    <description>Change in SARS-CoV-2 neutralizing antibody levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity</measure>
    <time_frame>days 7, 28, and 3 months post booster dose</time_frame>
    <description>Solicited and unsolicited. Events will be assessed by scheduled visits performed by nursing home´s nurse stuff. Telephone numbers, including the PI´s cell phone will be available 24/7 for reporting any unsolicited reaction. Reporting will follow national regulations available at the Institute of Public Health web page (https://www.ispch.cl/anamed/farmacovigilancia/vacunas/como-notificar-esavi/)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of booster dose</measure>
    <time_frame>In addition to the scheduled visits mentioned in Outcome 3, Telephone numbers, including the PI´s cell phone will be available 24/7 throughout the study (1 year) for reporting any unsolicited reaction.</time_frame>
    <description>Number of subjects presenting serious adverse events post booster dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">534</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Inactivated vaccine booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One standard IM CoronaVac dose (0.5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA vaccine booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One standard IM BNT162b2 dose (0.3 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viral vector vaccine booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One standard IM ChAdOx1 dose (0.5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution IM (0.3 mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.3 mL IM saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated vaccine booster</intervention_name>
    <description>0.5 mL IM</description>
    <arm_group_label>Inactivated vaccine booster</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA vaccine booster</intervention_name>
    <description>0.3 mL IM</description>
    <arm_group_label>mRNA vaccine booster</arm_group_label>
    <other_name>BNT162b2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viral vector vaccine booster</intervention_name>
    <description>0.5 mL IM</description>
    <arm_group_label>Viral vector vaccine booster</arm_group_label>
    <other_name>ChAdOx1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Full immunization with CoronaVac (2 doses; 0,28) prior to April 15, 2021&#xD;
&#xD;
          -  Being a resident of any of the eligible Nursing Homes (located in the Metropolitan&#xD;
             Region of Chile)&#xD;
&#xD;
          -  Healthcare workers of one of the eligible Nursing Homes.&#xD;
&#xD;
          -  Healthcare workers of Hospital de Urgencia Asistencia Publica (HUAP, Santiago, Chile)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of Covid-19&#xD;
&#xD;
          -  Not able to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ELEAMs (Nursing Homes)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Urgencia Asistencia Publica</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad del Desarrollo</investigator_affiliation>
    <investigator_full_name>Rafael Araos</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>covid-19</keyword>
  <keyword>inactivated vaccine</keyword>
  <keyword>booster</keyword>
  <keyword>Chile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Owing to data privacy regulations, the individual-level data in this study cannot be shared (Law N19.628).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

